5 July 2024
Incanthera plc
("Incanthera" the "Company")
Investor Evening
Aquis Stock Exchange and Investor Hub
Incanthera plc (AQSE:INC), the company specially focused on innovative technologies in dermatology and oncology, is pleased to announce its participation in "The Pub Test" Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.
The Company's Chairman, Tim McCarthy, will engage in a fireside conversation designed especially for private investors. This setting offers a unique opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.
All attendees will have the chance to network over drinks and a buffet.
To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024
Commenting on the event, Tim McCarthy, said:
"We have been fortunate to attend and present at a number of investor events recently and we always receive invaluable feedback and commentary from engaging with our shareholders and supporters.
We value the opportunity to share our vision and answer any questions investors may have at this event for shareholders, potential shareholders, and stakeholders. Co-hosted by Aquis Exchange and Investor Hub, we know it will be a great evening."
RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.
**ENDS**
For further information please contact:
| Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communications |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
| | |
| Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney | +44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
